Why Exact Sciences Stock Blasted Nearly 24% Higher Today

Source The Motley Fool

Key Points

  • The cancer diagnostics specialist might, just might, be on the verge of selling itself.

  • The apparent would-be buyer is a top name in the U.S. pharmaceutical industry.

  • 10 stocks we like better than Exact Sciences ›

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24% higher in price as a result.

Pinpointing the Exact reason

In an article published that morning and updated in the afternoon, Bloomberg reported that pharmaceutical sector mainstay Abbott Laboratories appears to be on the brink of acquiring Exact Sciences.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Person in a lab gazing into a microscope.

Image source: Getty Images.

Citing unidentified "people familiar with the matter," Bloomberg added that the two healthcare companies are discussing the terms of a buyout. These talks are apparently well advanced, as the article's sources said a deal could be announced within a matter of days.

That said, this is no guarantee at this stage that a buyout will be agreed, those sources added. It may be delayed or not occur at all.

Neither Abbott nor Exact Sciences opted to comment on the story when contacted by the financial news agency.

Beware speculation

It's always risky to trade in or out of a stock purely on buyout speculation -- and despite the apparently late-stage status of the talks, any Abbott/Exact deal remains speculative as of this writing (early evening on Wednesday).

A near 24% jump in share price means that, most likely, the bulk of any premium being paid by a potential buyer has already been factored into the latter's stock price. I'd advise being very careful with this one.

Should you invest $1,000 in Exact Sciences right now?

Before you buy stock in Exact Sciences, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exact Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $615,279!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,111,712!*

Now, it’s worth noting Stock Advisor’s total average return is 1,022% — a market-crushing outperformance compared to 188% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Forecast: XAU/USD recovers above $4,100, hawkish Fed might cap gainsGold price (XAU/USD) recovers some lost ground to near $4,105, snapping the two-day losing streak during the early European session on Friday. The precious metal edges higher on the softer US Dollar (USD).  Traders will take more cues from the Fedspeak later on Monday.
Author  FXStreet
Nov 17, Mon
Gold price (XAU/USD) recovers some lost ground to near $4,105, snapping the two-day losing streak during the early European session on Friday. The precious metal edges higher on the softer US Dollar (USD).  Traders will take more cues from the Fedspeak later on Monday.
placeholder
Ethereum Edges Toward Long-Term Holders’ Cost Basis, Now Only 8% Above Key Accumulation LevelEthereum is trading near $3,150 and just 8% above a key $2,895 long-term holders’ cost basis, with on-chain flows, macro uncertainty and support around $3,000–$2,800 all shaping what comes next for ETH.
Author  Mitrade
Nov 18, Tue
Ethereum is trading near $3,150 and just 8% above a key $2,895 long-term holders’ cost basis, with on-chain flows, macro uncertainty and support around $3,000–$2,800 all shaping what comes next for ETH.
placeholder
Ethereum Dips Below $3,000: Is the Bull Market at an End?Ethereum's price plunged below $3,000 for the first time in four months, marking growing concerns of a potential end to the bull market.
Author  Mitrade
Nov 18, Tue
Ethereum's price plunged below $3,000 for the first time in four months, marking growing concerns of a potential end to the bull market.
placeholder
Bitcoin Falls Below $90K: BitMine & Bitwise Executives Predict Market Bottom This Week​Bitcoin's recent drop below $90,000 may signal a market bottom, according to industry leaders.
Author  Mitrade
21 hours ago
​Bitcoin's recent drop below $90,000 may signal a market bottom, according to industry leaders.
placeholder
Top 3 Price Prediction: Bitcoin, Ethereum, Ripple – BTC, ETH and XRP Look for a Foothold After a Sharp ShakeoutBitcoin trades near $92,600 after a dip below $90,000, while Ethereum around $3,118 and XRP near $2.21–$2.23 sit on key support zones, as BTC, ETH and XRP all try to turn a sharp correction into a tradable rebound rather than a deeper slide.
Author  Mitrade
20 hours ago
Bitcoin trades near $92,600 after a dip below $90,000, while Ethereum around $3,118 and XRP near $2.21–$2.23 sit on key support zones, as BTC, ETH and XRP all try to turn a sharp correction into a tradable rebound rather than a deeper slide.
goTop
quote